OurCrowd portfolio company SaNOtize says that a UK clinical trial has delivered solid results as COVID-19 treatment. A self-administered nasal spray is said to reduce the viral load by more than 95% in 24 hours and by 99% in 72 hours. Trial results indicated that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placebo. Read...
Read MoreUtilizing DreaMed Diabetes’s Advisor Pro software, the prestigious health system will onboard 100 people with diabetes to assess the workflow, satisfaction, and financial aspects of an AI-based decision support system in a protocol that allows for both virtual and in-person visits. Read...
Read MoreVANCOUVER, British Columbia & SURREY, England–(BUSINESS WIRE)– Biotech company SaNOtize Research & Development Corp., (SaNOtize), Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, UK, and Berkshire and Surrey Pathology Services, UK, today announced results of clinical trials indicating that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe and effective antiviral treatment that could prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms and damage in those already infected. Read more...
Read MoreVANCOUVER — A B.C. biotech firm says it has developed an effective treatment for anyone who’s contracted COVID-19, and is now seeking federal approval for emergency use of the product. Following months of clinical trials, Vancouver-based SaNOtize says its nasal spray has been found to reduce COVID-19 levels by 95 per cent within 24 hours, and more than 99 per cent in under three days. Watch...
Read MoreThe drugmaker has completed a Phase 2 clinical trial in the UK, Israeli CEO says treatment can help vaccines defeat the pandemic. Read more...
Read More
